All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Business Development & Partnerships

Foresee Pharmaceuticals, Primevera Therapeutics partner on MMP-12 inhibitors, $10M upfront, $574.5M milestones
Licensing deal, inflammatory disease, small molecule, milestone payments, equity investment - Read more

Acuitas Therapeutics takes majority stake in RNA Technologies & Therapeutics for undisclosed sum
Acquisition, gene therapy, manufacturing, RNA therapeutics - Read more

GSK, Noetik partner on cancer AI platform licensing, $50M upfront and milestones
Licensing deal, oncology, AI/ML, milestone payments - Read more

Storm Therapeutics, AlidaBio collaborate on RNA-targeting cancer therapies using sequencing platforms
Research collaboration, oncology, drug discovery, small molecule, biomarker development - Read more

Iktos, Servier collaborate on AI-driven small molecule discovery across multiple targets, €1B+ ($1.17B+) potential deal value
Research collaboration, AI/ML, small molecule, oncology, neurological, milestone payments - Read more

Genmab, Anthropic partner on Claude-powered AI systems for clinical development operations
Research collaboration, AI/ML, clinical development, oncology - Read more

Pfizer, Gordian Bio partner on obesity target discovery using in vivo genomics platform
Research collaboration, obesity, drug discovery, in vivo functional genomics - Read more

PRESENTED BY SCIENCE 2 SALES
Cold calling in the life sciences - free webinar!

By popular demand, we’re running two webinars on cold calling in the life sciences - our first one was a hit, and there’s one more next week!

We’ll be covering:
• Why cold calling is so powerful right now (hint: points at all the AI everywhere)
• What is (and isn't) cold calling
• When it's worth it (sometimes it's not!)
• Mindset, strategies, and the technical bits behind doing cold calling

And probably a bunch more things - also a special guest 👀

Email [email protected] to get your invite

✅ More Good News ✅

THE GOOD
Clinical Trials

Eli Lilly's Zepbound (tirzepatide)-Taltz combo shows Ph3b success in psoriatic arthritis patients with obesity
Small molecule, autoimmune, GLP-1 receptor agonist, psoriatic arthritis, combination therapy, obesity - Read more

Ollin Biosciences' OLN324 bispecific antibody outperforms Vabysmo in Ph1b diabetic macular edema trial, eyes Ph3
Antibody, retinal disease, bispecific antibody, diabetic macular edema, VEGF target - Read more

Immuneering's atebimetinib (IMM-1-104) shows exceptional 12-month survival in Ph2 pancreatic cancer trial targeting MEK pathway
Small molecule, cancer, MEK inhibitor, pancreatic cancer, combination therapy - Read more

THE GOOD
Company Launches

Alveus Therapeutics launches with $160M Series A to advance MariTide-like obesity drug ALV-100
Fusion protein, obesity, strategic, major transaction - Read more

THE GOOD
Fundraises

Parabilis raises $305M Series F, advancing cancer drug zolucatetide toward registration
Cancer, peptide therapy, rare disease, clinical-stage - Read more

Aktis raises $318M IPO, developing radiopharmaceutical drugs targeting cancer tumors
Radiopharmaceuticals, oncology, clinical-stage, protein targeting - Read more

Beacon Therapeutics raises $75M+ Series C, clinical-stage ocular disease treatments
Ocular diseases, rare disease, clinical-stage, biotechnology - Read more

EpiBiologics raises $107M Series B for protein-degrading cancer drug development
Cancer, protein degradation, antibody, clinical-stage - Read more

Diagonal Therapeutics raises $125M Series B for clustering antibody drug development
Antibody, rare disease, clustering technology, clinical-stage - Read more

TECregen raises $12.6M seed funding, developing thymus regeneration immunotherapy platform
Immunotherapy, thymus regeneration, platform technology, preclinical - Read more

Boltz raises $28M seed, AI drug discovery platform partnering with Pfizer
AI/ML platform, drug discovery, small molecule, protein design, platform technology - Read more

Nocion Therapeutics extends Series B to $93M for chronic cough treatment development
Small molecule, pain management, respiratory disease, preclinical - Read more

Enodia Therapeutics raises $25M Seed, small-molecule therapies for targeted protein degradation
Small molecule, AI/ML platform, protein degradation, platform technology - Read more

Vizgen raises $48M Series E, spatial biology and multiomics tools production
Spatial biology, platform technology, multiomics, manufacturing - Read more [Paywall]

THE GOOD
Market Reports

Massachusetts biopharma VC funding hits $6.85B in 2025, analysts optimistic for 2026 recovery
Oncology, neurological, venture capital, financial, strategic, investment - Read more

THE GOOD
Strategic Plans

Nautilus Biotechnology launches Early Access Program for single-molecule proteomics platform with tau proteoforms assay
Proteomics platform, neurological, strategic, operational - Read more

PRESENTED BY YOU?
Get the attention of 2500+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Approvals & Labels

FDA rejects Vanda Pharmaceuticals' Hetlioz for jet lag indication citing disagreements over clinical trial methodology
Small molecule, sleep disorders, melatonin receptor agonist, jet lag, circadian rhythm - Read more

THE BAD
Layoffs

Tessera Therapeutics plans to lay off 90 employees starting March 8 despite recent Regeneron partnership
Gene therapy, rare disease, operational, cost reduction - Read more

InflaRx cuts 30% of staff, reduces COVID drug spending to focus on lead asset izicopan
Small molecule, autoimmune, cost reduction, operational - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here